KR101445398B1 - 활성 성분을 신속 방출하는 고형 경구 투여용 제약 투여형태 - Google Patents
활성 성분을 신속 방출하는 고형 경구 투여용 제약 투여형태 Download PDFInfo
- Publication number
- KR101445398B1 KR101445398B1 KR1020087010702A KR20087010702A KR101445398B1 KR 101445398 B1 KR101445398 B1 KR 101445398B1 KR 1020087010702 A KR1020087010702 A KR 1020087010702A KR 20087010702 A KR20087010702 A KR 20087010702A KR 101445398 B1 KR101445398 B1 KR 101445398B1
- Authority
- KR
- South Korea
- Prior art keywords
- active ingredient
- delete delete
- amorphous
- formulation
- capsule
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102005047561.2 | 2005-10-04 | ||
DE102005047561A DE102005047561A1 (de) | 2005-10-04 | 2005-10-04 | Feste, oral applizierbare pharmazeutische Darreichungsformen mit schneller Wirkstofffreisetzung |
PCT/EP2006/009178 WO2007039122A2 (de) | 2005-10-04 | 2006-09-21 | Feste, oral applizierbare pharmazeutische darreichungsformen mit schneller wirkstofffreisetzung |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20080067638A KR20080067638A (ko) | 2008-07-21 |
KR101445398B1 true KR101445398B1 (ko) | 2014-09-26 |
Family
ID=37852804
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020087010702A KR101445398B1 (ko) | 2005-10-04 | 2006-09-21 | 활성 성분을 신속 방출하는 고형 경구 투여용 제약 투여형태 |
Country Status (27)
Country | Link |
---|---|
US (1) | US8586082B2 (es) |
EP (1) | EP1957048A2 (es) |
JP (1) | JP5147703B2 (es) |
KR (1) | KR101445398B1 (es) |
CN (1) | CN101321517B (es) |
AR (1) | AR056564A1 (es) |
AU (1) | AU2006299192B2 (es) |
BR (1) | BRPI0616874A2 (es) |
CA (1) | CA2624306C (es) |
CR (1) | CR9864A (es) |
CU (1) | CU23808B7 (es) |
DE (1) | DE102005047561A1 (es) |
DO (1) | DOP2006000209A (es) |
EC (1) | ECSP088339A (es) |
GT (1) | GT200600445A (es) |
HK (1) | HK1127284A1 (es) |
IL (1) | IL190618A0 (es) |
MY (1) | MY143351A (es) |
NZ (1) | NZ567094A (es) |
PE (1) | PE20070588A1 (es) |
RU (1) | RU2440119C2 (es) |
SV (1) | SV2009002857A (es) |
TW (1) | TWI389691B (es) |
UA (1) | UA90545C2 (es) |
UY (1) | UY29835A1 (es) |
WO (1) | WO2007039122A2 (es) |
ZA (1) | ZA200802873B (es) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19962924A1 (de) | 1999-12-24 | 2001-07-05 | Bayer Ag | Substituierte Oxazolidinone und ihre Verwendung |
DE10129725A1 (de) | 2001-06-20 | 2003-01-02 | Bayer Ag | Kombinationstherapie substituierter Oxazolidinone |
DE10300111A1 (de) | 2003-01-07 | 2004-07-15 | Bayer Healthcare Ag | Verfahren zur Herstellung von 5-Chlor-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamid |
DE10355461A1 (de) | 2003-11-27 | 2005-06-23 | Bayer Healthcare Ag | Verfahren zur Herstellung einer festen, oral applizierbaren pharmazeutischen Zusammensetzung |
DE102004062475A1 (de) * | 2004-12-24 | 2006-07-06 | Bayer Healthcare Ag | Feste, oral applizierbare pharmazeutische Darreichungsformen mit modifizierter Freisetzung |
EP1685841A1 (en) | 2005-01-31 | 2006-08-02 | Bayer Health Care Aktiengesellschaft | Prevention and treatment of thromboembolic disorders |
DE102005045518A1 (de) | 2005-09-23 | 2007-03-29 | Bayer Healthcare Ag | 2-Aminoethoxyessigsäure-Derivate und ihre Verwendung |
RU2578602C2 (ru) | 2005-10-04 | 2016-03-27 | Байер Интеллектуэль Проперти Гмбх | Способ получения 5-хлор-n-(5s)-2-оксо-3-[4-(3-оксо-морфолинил)-фенил]-1,3-оксазолидин-5-ил}-метил)-2-тиофенкарбоксамида в модификации ii (варианты) |
DE102005047561A1 (de) | 2005-10-04 | 2007-04-05 | Bayer Healthcare Ag | Feste, oral applizierbare pharmazeutische Darreichungsformen mit schneller Wirkstofffreisetzung |
CN102105138A (zh) | 2008-07-08 | 2011-06-22 | 德国通益药业有限公司 | 包含5-氯-n-({(5s)-2-氧代-3-[4-(3-氧代-4-吗啉基)-苯基]-1,3-噁唑烷-5-基}-甲基)-2-噻吩羧酰胺的药物组合物 |
US20110189279A1 (en) * | 2008-08-11 | 2011-08-04 | Ratiopharm Gmbh | Pharmaceutical compositions with modified release properties comprising 5-chloro-n-(-methyl)-2-thiophencarboxamid |
US7816355B1 (en) | 2009-04-28 | 2010-10-19 | Apotex Pharmachem Inc | Processes for the preparation of rivaroxaban and intermediates thereof |
GB0909680D0 (en) * | 2009-06-05 | 2009-07-22 | Euro Celtique Sa | Dosage form |
LT2442799T (lt) | 2009-06-18 | 2016-12-27 | Krka, Tovarna Zdravil, D.D., Novo Mesto | Kieta farmacinė kompozicija, apimanti rivaroksabaną |
EP2266541A1 (en) | 2009-06-18 | 2010-12-29 | Krka Tovarna Zdravil, D.D., Novo Mesto | Solid pharmaceutical composition comprising rivaroxaban |
EP2485715A1 (en) | 2009-10-06 | 2012-08-15 | Ratiopharm GmbH | Pharmaceutical compositions comprising rivaroxaban |
EP2308472A1 (en) | 2009-10-06 | 2011-04-13 | ratiopharm GmbH | Pharmaceutical compositions comprising rivaroxaban |
US9901540B2 (en) | 2010-05-10 | 2018-02-27 | Euro-Celtique S.A. | Combination of active loaded granules with additional actives |
GB2492037A (en) | 2010-05-10 | 2012-12-19 | Euro Celtique Sa | Pharmaceutical compositions comprising hydromorphone and naloxone |
US9993433B2 (en) | 2010-05-10 | 2018-06-12 | Euro-Celtique S.A. | Manufacturing of active-free granules and tablets comprising the same |
US8906949B2 (en) * | 2010-05-21 | 2014-12-09 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Orally disintegrating tablets of zolmitriptan and process for preparing the same |
EP2404920A1 (en) | 2010-07-06 | 2012-01-11 | Sandoz AG | Crystalline form of Rivaroxaban dihydrate |
DE102010063127A1 (de) | 2010-12-15 | 2012-06-21 | Bayer Schering Pharma Aktiengesellschaft | Flüssige, oral applizierbare pharmazeutische Zusammensetzungen enthaltend 5-Chlor-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamid |
US20130064888A1 (en) | 2011-08-08 | 2013-03-14 | Roey Solomonovich | Pharmaceutical formulations |
EP2808011A1 (en) * | 2013-05-29 | 2014-12-03 | Sandoz Ag | Process for the preparation of a pharmaceutical composition comprising Rivaroxaban |
CN103550166A (zh) * | 2013-10-31 | 2014-02-05 | 江苏阿尔法药业有限公司 | 一种利伐沙班口服微球制剂 |
AU2014350135B2 (en) | 2013-11-13 | 2017-08-31 | Euro-Celtique S.A. | Hydromorphone and naloxone for treatment of pain and opioid bowel dysfunction syndrome |
WO2015124995A1 (en) | 2014-02-19 | 2015-08-27 | Aurobindo Pharma Ltd | Solid dosage forms of rivaroxaban |
KR101499867B1 (ko) * | 2014-04-22 | 2015-03-06 | 에스케이케미칼주식회사 | 활성 성분 (i) 함유 조성물 및 이의 제조 방법 |
KR102333463B1 (ko) * | 2014-07-02 | 2021-12-03 | 한미약품 주식회사 | 리바록사반을 포함하는 경구 투여용 약학 조성물 및 이의 제조방법 |
CN104666262B (zh) * | 2015-02-03 | 2017-09-15 | 山东新时代药业有限公司 | 一种利伐沙班片 |
EP3441065A4 (en) * | 2016-04-06 | 2019-11-20 | Astellas Pharma Inc. | HIGH-QUIET THREE-DIMENSIONAL MOLDING, THREE-DIMENSIONAL QUICK-RELEASE MOLDING FILAMENT, AND QUICK-RELEASE THREE-DIMENSIONAL MOLDING MATERIAL |
EP3565532A4 (en) * | 2017-01-04 | 2020-10-28 | Bonayo Lifesciences Private Limited | ORAL DISPERSIBLE FILM COMPOSITION |
JP7305527B2 (ja) * | 2018-11-30 | 2023-07-10 | 大原薬品工業株式会社 | リバーロキサバンと嬌味剤を含有する固形製剤 |
US11073030B1 (en) * | 2020-05-21 | 2021-07-27 | Raytheon Technologies Corporation | Airfoil attachment for gas turbine engines |
JP7511596B2 (ja) * | 2021-03-10 | 2024-07-05 | 日本ジェネリック株式会社 | リバーロキサバン含有錠剤 |
GR1010231B (el) | 2021-03-24 | 2022-05-10 | Φαρματεν Α.Β.Ε.Ε., | Φαρμακευτικο σκευασμα που περιλαμβανει ριβαροξαμπανη και μεθοδος παρασκευης αυτου |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001047919A1 (de) | 1999-12-24 | 2001-07-05 | Bayer Aktiengesellschaft | Substituierte oxazolidinone und ihre verwendung im gebiet der blutgerinnung |
WO2005060940A2 (de) * | 2003-11-27 | 2005-07-07 | Bayer Healthcare Ag | Verfahren zur herstellung einer festen, oral applizierbaren pharmazeutischen zusammensetzung |
Family Cites Families (83)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US629201A (en) * | 1898-07-13 | 1899-07-18 | Adolph Mueller | Means for preventing sparking when and breaking electric circuits. |
US2811555A (en) | 1955-05-02 | 1957-10-29 | Eastman Kodak Co | Reduction of 2-nitroso-5-diethylaminotoluene |
US3279880A (en) | 1965-07-12 | 1966-10-18 | Eastman Kodak Co | Polyester textile material dyed with 1-hydroxy-4-n-p-(2'-pyrrolidonyl-1-) phenyl-amino anthraquinones |
LU80081A1 (fr) | 1977-08-26 | 1979-05-15 | Delalande Sa | Nouvelles hydroxymethyl-5 oxazolidinones-2,leur procede de preparation et leur application therapeutique |
US4128654A (en) | 1978-02-10 | 1978-12-05 | E. I. Du Pont De Nemours And Company | 5-Halomethyl-3-phenyl-2-oxazolidinones |
US4500519A (en) | 1978-11-06 | 1985-02-19 | Choay S.A. | Mucopolysaccharides having biological properties, preparation and method of use |
US4344934A (en) * | 1978-11-20 | 1982-08-17 | American Home Products Corporation | Therapeutic compositions with enhanced bioavailability |
US4327725A (en) | 1980-11-25 | 1982-05-04 | Alza Corporation | Osmotic device with hydrogel driving member |
HU190072B (en) | 1983-03-11 | 1986-08-28 | Biogal Gyogyszergyar,Hu | Process for production of medical preparatives with sinergetic influence |
NZ206600A (en) | 1983-05-11 | 1987-01-23 | Alza Corp | Osmotic drug delivery device |
US4765989A (en) * | 1983-05-11 | 1988-08-23 | Alza Corporation | Osmotic device for administering certain drugs |
ES8506659A1 (es) | 1983-06-07 | 1985-08-01 | Du Pont | Un procedimiento para la preparacion de nuevos derivados del amino-metil-oxooxazolidinil-benzeno. |
EP0316594B1 (en) | 1987-10-21 | 1993-09-29 | The Du Pont Merck Pharmaceutical Company | Aminomethyl oxooxazolidinyl ethenylbenzene derivatives useful as antibacterial agents |
US4977173A (en) | 1987-10-21 | 1990-12-11 | E. I. Du Pont De Nemours And Company | Aminomethyl oxooxazolidinyl ethenylbenzene derivatives useful as antibacterial agents |
DE3822650A1 (de) | 1988-07-05 | 1990-02-01 | Boehringer Mannheim Gmbh | Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel |
US5254577A (en) | 1988-07-29 | 1993-10-19 | The Du Pont Merck Pharmaceutical Company | Aminomethyloxooxazolidinyl arylbenzene derivatives useful as antibacterial agents |
US4948801A (en) | 1988-07-29 | 1990-08-14 | E. I. Du Pont De Nemours And Company | Aminomethyloxooxazolidinyl arylbenzene derivatives useful as antibacterial agents |
ATE146783T1 (de) | 1991-11-01 | 1997-01-15 | Upjohn Co | Substituierte aryl- und heteroaryl- phenyloxazolidinone |
SK283420B6 (sk) | 1992-05-08 | 2003-07-01 | Pharmacia & Upjohn Company | Antimikrobiálne oxazolidinóny obsahujúce substituované diazínové skupiny |
US5349045A (en) | 1993-01-26 | 1994-09-20 | United States Surgical Corporation | Polymer derived from cyclic amide and medical devices manufactured therefrom |
EP0623615B1 (de) | 1993-05-01 | 1999-06-30 | MERCK PATENT GmbH | Substituierte 1-Phenyl-oxazolidin-2-on Derivate, deren Herstellung und deren Verwendung als Adhäsionsrezeptor-Antagonisten |
US5564571A (en) | 1993-07-19 | 1996-10-15 | Cembre S.P.A. | Strip for electrical connectors |
US5688792A (en) | 1994-08-16 | 1997-11-18 | Pharmacia & Upjohn Company | Substituted oxazine and thiazine oxazolidinone antimicrobials |
DE4332384A1 (de) | 1993-09-23 | 1995-03-30 | Merck Patent Gmbh | Adhäsionsrezeptor-Antagonisten III |
DE69615002T2 (de) | 1995-02-03 | 2002-06-13 | Pharmacia & Upjohn Co., Kalamazoo | Durch hetero-aromatische ring substituierte phenyloxazolidinone als antimikrobielles mittel |
HRP960159A2 (en) | 1995-04-21 | 1997-08-31 | Bayer Ag | Benzocyclopentane oxazolidinones containing heteroatoms |
DE19524765A1 (de) | 1995-07-07 | 1997-01-09 | Boehringer Mannheim Gmbh | Neue Oxazolidinonderivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel |
SK283487B6 (sk) | 1995-09-01 | 2003-08-05 | Pharmacia And Upjohn Company | Fenyloxazolidinóny majúce C-C väzbu v 4 až 8 členných heterocyklických kruhoch |
DE69631347T2 (de) | 1995-09-15 | 2004-10-07 | Upjohn Co | Aminoaryl oxazolidinone n-oxide |
DE19601264A1 (de) | 1996-01-16 | 1997-07-17 | Bayer Ag | Pyrido-annellierte Thienyl- und Furanyl-Oxazolidinone |
DE19604223A1 (de) | 1996-02-06 | 1997-08-07 | Bayer Ag | Neue substituierte Oxazolidinone |
HRP970049A2 (en) | 1996-02-06 | 1998-04-30 | Bayer Ag | New heteroaryl oxazolidinones |
GB9614238D0 (en) | 1996-07-06 | 1996-09-04 | Zeneca Ltd | Chemical compounds |
DK1175902T3 (da) | 1996-07-15 | 2005-12-19 | Sankyo Co | Anvendelse CS-866 (olmesartan) til fremstillingen af et medikament til behandling af arteriosclerose |
JPH10175816A (ja) * | 1996-12-18 | 1998-06-30 | Toray Dow Corning Silicone Co Ltd | 化粧品原料、化粧品、および化粧品の製造方法 |
FR2758459B1 (fr) * | 1997-01-17 | 1999-05-07 | Pharma Pass | Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation |
US5935724A (en) | 1997-04-04 | 1999-08-10 | Wilson Greatbatch Ltd. | Electrochemical cell having multiplate electrodes with differing discharge rate regions |
US6273913B1 (en) | 1997-04-18 | 2001-08-14 | Cordis Corporation | Modified stent useful for delivery of drugs along stent strut |
JP2002501530A (ja) | 1997-05-30 | 2002-01-15 | ファルマシア・アンド・アップジョン・カンパニー | チオカルボニル官能基を有するオキサゾリジノン抗菌剤 |
KR20010021645A (ko) | 1997-07-11 | 2001-03-15 | 로렌스 티. 마이젠헬더 | 티아디아졸릴 및 옥사디아졸릴 페닐 옥사졸리디논 항균제 |
DE19730847A1 (de) | 1997-07-18 | 1999-01-28 | Bayer Ag | Tricyclisch substituierte Oxazolidinone |
GB9715894D0 (en) | 1997-07-29 | 1997-10-01 | Zeneca Ltd | Heterocyclic derivatives |
DE19747261A1 (de) | 1997-10-25 | 1999-04-29 | Bayer Ag | Osmotisches Arzneimittelfreisetzungssystem |
DK1030852T3 (da) | 1997-11-12 | 2003-12-22 | Upjohn Co | Oxazolidinonderivater og farmaceutiske præparater |
US6083967A (en) | 1997-12-05 | 2000-07-04 | Pharmacia & Upjohn Company | S-oxide and S,S-dioxide tetrahydrothiopyran phenyloxazolidinones |
DE19755268A1 (de) | 1997-12-12 | 1999-06-17 | Merck Patent Gmbh | Benzamidinderivate |
BR9907183A (pt) | 1998-01-23 | 2003-06-10 | Versicor Inc | Colet neas combinatórias de oxazolidinona, composições e processos de preparação |
ATE346050T1 (de) | 1998-01-27 | 2006-12-15 | Aventis Pharma Inc | Substituierte oxoazaheterocyclyl faktor xa hemmer |
US20010029351A1 (en) | 1998-04-16 | 2001-10-11 | Robert Falotico | Drug combinations and delivery devices for the prevention and treatment of vascular disease |
CZ291945B6 (cs) | 1998-05-18 | 2003-06-18 | Pharmacia & Upjohn Company | Použití oxazolidinonových antibakteriálních látek a derivátů argininu a farmaceutická kompozice |
DE19842753A1 (de) * | 1998-09-18 | 2000-03-23 | Bayer Ag | Agitationsunabhängige pharmazeutische Retardzubereitungen und Verfahren zu ihrer Herstellung |
JP2000281561A (ja) * | 1999-03-26 | 2000-10-10 | Ajinomoto Co Inc | 新規溶媒法固体分散体製剤 |
US6413981B1 (en) | 1999-08-12 | 2002-07-02 | Ortho-Mcneil Pharamceutical, Inc. | Bicyclic heterocyclic substituted phenyl oxazolidinone antibacterials, and related compositions and methods |
PE20010851A1 (es) | 1999-12-14 | 2001-08-17 | Upjohn Co | Esteres del acido benzoico de oxazolidinonas que tienen un substituyente hidroxiacetilpiperazina |
CN1221548C (zh) | 1999-12-21 | 2005-10-05 | 法玛西雅厄普约翰美国公司 | 含有砜亚氨基官能团的噁唑烷酮 |
EP1245573A1 (en) | 1999-12-28 | 2002-10-02 | Ajinomoto Co., Inc. | Aspartame derivative crystals |
US6514529B2 (en) * | 2000-03-22 | 2003-02-04 | Pharmacia & Upjohn Company | Oxazolidinone tablet formulation |
DE60135674D1 (de) * | 2000-10-24 | 2008-10-16 | Ajinomoto Kk | Nateglinid enthaltende präparate |
DE10105989A1 (de) | 2001-02-09 | 2002-08-14 | Bayer Ag | Substituierte Oxazolidinone und ihre Verwendung |
DE10110438A1 (de) | 2001-03-05 | 2002-09-19 | Bayer Ag | Substituierte 2-Oxy-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung |
DE10110747A1 (de) | 2001-03-07 | 2002-09-12 | Bayer Ag | Substituierte 2,6-Diamino-3,5-dicyano-4-aryl-pyridine und ihre Verwendung |
DE10110754A1 (de) | 2001-03-07 | 2002-09-19 | Bayer Ag | Substituierte 2-Thio-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung |
DE10115945A1 (de) | 2001-03-30 | 2002-10-02 | Bayer Ag | Substituierte 2-Carba-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung |
DE10115922A1 (de) | 2001-03-30 | 2002-10-10 | Bayer Ag | Cyclisch substituierte 2-Thio-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung |
DE10129725A1 (de) | 2001-06-20 | 2003-01-02 | Bayer Ag | Kombinationstherapie substituierter Oxazolidinone |
DE10152460A1 (de) | 2001-10-24 | 2003-05-08 | Bayer Ag | Stents |
DE10238113A1 (de) | 2001-12-11 | 2003-06-18 | Bayer Ag | Substituierte 2-Thio-3,5-dicyano-4-phenyl-6-aminopyridine und ihre Verwendung |
US20030161882A1 (en) | 2002-02-01 | 2003-08-28 | Waterman Kenneth C. | Osmotic delivery system |
DE10248619A1 (de) * | 2002-10-18 | 2004-04-29 | Bayer Ag | Verfahren zur Herstellung pulverförmiger Wirkstoff-Formulierungen mit kompressiblen Fluiden |
DE10300111A1 (de) | 2003-01-07 | 2004-07-15 | Bayer Healthcare Ag | Verfahren zur Herstellung von 5-Chlor-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamid |
US20040185097A1 (en) | 2003-01-31 | 2004-09-23 | Glenmark Pharmaceuticals Ltd. | Controlled release modifying complex and pharmaceutical compositions thereof |
DE10325989A1 (de) * | 2003-06-07 | 2005-01-05 | Glatt Gmbh | Verfahren zur Herstellung von und daraus resultierende Mikropellets sowie deren Verwendung |
CN1819817A (zh) * | 2003-07-09 | 2006-08-16 | 株式会社钟根堂 | 一种泰克利玛的固体分散体 |
BRPI0418330A (pt) * | 2003-12-31 | 2007-05-02 | Pfizer Prod Inc | composições sólidas de drogas de solubilidade baixa e poloxámeros |
DE102004002044A1 (de) | 2004-01-15 | 2005-08-04 | Bayer Healthcare Ag | Herstellverfahren |
KR100629771B1 (ko) * | 2004-01-27 | 2006-09-28 | 씨제이 주식회사 | 결정성이 감소되거나 무정형화된 올티프라즈의 제조방법 |
DE102004062475A1 (de) | 2004-12-24 | 2006-07-06 | Bayer Healthcare Ag | Feste, oral applizierbare pharmazeutische Darreichungsformen mit modifizierter Freisetzung |
EP1685841A1 (en) | 2005-01-31 | 2006-08-02 | Bayer Health Care Aktiengesellschaft | Prevention and treatment of thromboembolic disorders |
DE102005045518A1 (de) | 2005-09-23 | 2007-03-29 | Bayer Healthcare Ag | 2-Aminoethoxyessigsäure-Derivate und ihre Verwendung |
RU2578602C2 (ru) | 2005-10-04 | 2016-03-27 | Байер Интеллектуэль Проперти Гмбх | Способ получения 5-хлор-n-(5s)-2-оксо-3-[4-(3-оксо-морфолинил)-фенил]-1,3-оксазолидин-5-ил}-метил)-2-тиофенкарбоксамида в модификации ii (варианты) |
DE102005047558A1 (de) | 2005-10-04 | 2008-02-07 | Bayer Healthcare Ag | Kombinationstherapie substituierter Oxazolidinone zur Prophylaxe und Behandlung von cerebralen Durchblutungsstörungen |
DE102005047561A1 (de) | 2005-10-04 | 2007-04-05 | Bayer Healthcare Ag | Feste, oral applizierbare pharmazeutische Darreichungsformen mit schneller Wirkstofffreisetzung |
DE102005048824A1 (de) | 2005-10-10 | 2007-04-12 | Bayer Healthcare Ag | Behandlung und Prophylaxe von Mikroangiopathien |
-
2005
- 2005-10-04 DE DE102005047561A patent/DE102005047561A1/de not_active Withdrawn
-
2006
- 2006-09-21 NZ NZ567094A patent/NZ567094A/en unknown
- 2006-09-21 US US12/089,148 patent/US8586082B2/en active Active
- 2006-09-21 RU RU2008116831/15A patent/RU2440119C2/ru active
- 2006-09-21 CA CA2624306A patent/CA2624306C/en active Active
- 2006-09-21 JP JP2008533890A patent/JP5147703B2/ja active Active
- 2006-09-21 UA UAA200805665A patent/UA90545C2/ru unknown
- 2006-09-21 WO PCT/EP2006/009178 patent/WO2007039122A2/de active Application Filing
- 2006-09-21 MY MYPI20080998A patent/MY143351A/en unknown
- 2006-09-21 BR BRPI0616874-4A patent/BRPI0616874A2/pt not_active Application Discontinuation
- 2006-09-21 EP EP06792199A patent/EP1957048A2/de not_active Withdrawn
- 2006-09-21 CN CN2006800455481A patent/CN101321517B/zh active Active
- 2006-09-21 AU AU2006299192A patent/AU2006299192B2/en active Active
- 2006-09-21 KR KR1020087010702A patent/KR101445398B1/ko active IP Right Grant
- 2006-10-02 DO DO2006000209A patent/DOP2006000209A/es unknown
- 2006-10-03 UY UY29835A patent/UY29835A1/es not_active Application Discontinuation
- 2006-10-03 PE PE2006001198A patent/PE20070588A1/es not_active Application Discontinuation
- 2006-10-03 TW TW095136623A patent/TWI389691B/zh active
- 2006-10-04 GT GT200600445A patent/GT200600445A/es unknown
- 2006-10-04 AR ARP060104365A patent/AR056564A1/es unknown
-
2008
- 2008-04-02 ZA ZA200802873A patent/ZA200802873B/xx unknown
- 2008-04-02 SV SV2008002857A patent/SV2009002857A/es active IP Right Grant
- 2008-04-02 EC EC2008008339A patent/ECSP088339A/es unknown
- 2008-04-03 IL IL190618A patent/IL190618A0/en unknown
- 2008-04-03 CR CR9864A patent/CR9864A/es not_active Application Discontinuation
- 2008-04-04 CU CU20080052A patent/CU23808B7/es active IP Right Grant
-
2009
- 2009-06-04 HK HK09105035.7A patent/HK1127284A1/xx unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001047919A1 (de) | 1999-12-24 | 2001-07-05 | Bayer Aktiengesellschaft | Substituierte oxazolidinone und ihre verwendung im gebiet der blutgerinnung |
WO2005060940A2 (de) * | 2003-11-27 | 2005-07-07 | Bayer Healthcare Ag | Verfahren zur herstellung einer festen, oral applizierbaren pharmazeutischen zusammensetzung |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101445398B1 (ko) | 활성 성분을 신속 방출하는 고형 경구 투여용 제약 투여형태 | |
US11793809B2 (en) | Pharmaceutical compositions of nilotinib | |
EP2068839B1 (en) | Pharmaceutical compositions comprising nilotinib or its salt | |
EP1888040B1 (en) | Pharmaceutical compositions comprising imatinib and a release retardant | |
AU2004305226B2 (en) | Method for the production of a solid, orally applicable pharmaceutical composition | |
CA2412776C (en) | Compositions controlling release ph range and/or speed | |
AU763309B2 (en) | Bioenhanced formulations comprising eprosartan in oral solid dosage form | |
AU2012340759B2 (en) | Pharmaceutical formulations | |
SK284145B6 (sk) | Antifungálne prostriedky so zlepšenou biologickou dostupnosťou | |
RU2713428C1 (ru) | Частицы, содержащие аморфный эмпаглифлозин, способ их получения и содержащий их лекарственный препарат | |
CA3008634A1 (en) | Pharmaceutical compositions comprising phenylaminopyrimidine derivative | |
KR101441450B1 (ko) | 생체 이용률이 향상된 에프로살탄 고체 분산체, 이의 제조방법 및 용도 | |
KR102286499B1 (ko) | 레날리도마이드를 포함하는 약제학적 조성물 | |
KR20230155504A (ko) | (4s)-24-클로로-4-에틸-73-플루오로-35-메톡시-32,5-디옥소-14-(트리플루오로메틸)-32h-6-아자-3(4,1)-피리디나-1(1)-[1,2,3]트리아졸라-2(1,2),7(1)-디벤제나헵타판-74-카르복스아미드를 포함하는 제약 투여 형태 | |
KR102363727B1 (ko) | 생체이용률이 개선된 프란루카스트 함유 고형 제제의 조성물 및 그 제조방법 | |
JP2813792B2 (ja) | マレイン酸イルソグラジン経口投与用製剤およびその製造法 | |
EP3731823A1 (en) | A pharmaceutical formulation for oral administration comprising dabigatran etexilate |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
N231 | Notification of change of applicant | ||
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
N231 | Notification of change of applicant | ||
E90F | Notification of reason for final refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20180903 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20190829 Year of fee payment: 6 |